What does vivo capital do?

Vivo Capital is a healthcare focused investment firm formed in 1996 with over $2.2 billion under management. Vivo Capital is currently making investments from its $750M eighth fund into promising private and public healthcare companies in the U.S. and Greater China, from its $635M Opportunity fund into promising public healthcare companies,…

What is valuevivo Capital Fund IX?

Vivo Capital Fund IX and its predecessor funds are growth capital and private equity-focused investment vehicles investing in the healthcare industry. Vivo invests in product-driven companies that develop and commercialize therapeutics, including pharmaceuticals, biotechnology and medical devices.

How does the valuevivo Opportunity Fund work?

Vivo Opportunity Fund primarily invests in the global public equities of small and mid-cap biotechnology, pharmaceutical, healthcare and life science companies. The fund is long only and often invests directly into companies through various financing structures, including follow-ons, secondaries, PIPEs, ATM purchases, and IPOs.

Where does the major petrosal nerve leave the facial nerve?

The major petrosal nerve (GVE and GVA) leaves the facial nerve at the level of the geniculate ganglion. It is joined by sympathetic postganglionic fibers from the cranial cervical ganglion via the internal carotid plexus. These sympathetic fibers form the deep petrosal nerve.

Is vivo capital part of whalescore?

Vivo Capital is based out of Palo Alto. Their last reported 13F filing for Q2 2019 included $1,067,129,000 in managed 13F securities and a top 10 holdings concentration of 64.05%. Vivo Capital’s largest holding is Ascendis Pharma A/S ADR with shares held of 2,060,135. Vivo Capital has met the qualifications for inclusion in our WhaleScore system.

Why invest in valuevivo?

Vivo invests in product-driven companies that develop and commercialize therapeutics, including pharmaceuticals, biotechnology and medical devices. Our growth capital investments help our portfolio companies accelerate revenue ramp or fund product development to drive value creation.